Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness, Safety and Tolerability Study of RP-G28 for Symptoms Associated With Lactose Intolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects. Female subjects must be non-pregnant and non-lactating.~* 18 to 64 years of age inclusive at Screening~* Current or recent history of intolerance to milk and other dairy products~* Acceptable Baseline Lactose Intolerance Symptom Scores~* Acceptable Result on Baseline Hydrogen Breath Test~* Subjects must agree to refrain from all other treatments and products used for lactose intolerance during the study~Exclusion Criteria:~* Disorders known to be associated with abnormal GI motility~* History of surgery that alters the normal function of the gastrointestinal tract~* Past or present; organ transplant, chronic pancreatitis, pancreatic insufficiency, symptomatic biliary disease, Celiac disease, inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, irritable bowel syndrome (IBS)~* Active gastric or duodenal ulcers or history of severe ulcers~* Diabetes mellitus (type 1 or type 2)~* Congestive Heart Failure~* History of Human Immunodeficiency Virus (HIV), Hepatitis B or C~* Use of concurrent therapy(ies) for symptoms of lactose intolerance~* Uncontrolled BP defined as sitting systolic blood pressure (SBP) ≥160 mmHg or diastolic blood pressure (DBP) ≥95 mmHg at Visit 1~* History of ethanol abuse in the past 12 months~* History of drug abuse within 12 months~* History or presence of malignancy within the past 5 years (except basal cell or squamous cell carcinoma removed from a sun-exposed area)~* Use of any investigational drug or participation in any investigational study within 30 days prior to Screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- RP-G28 (Type: EXPERIMENTAL): Study Drug RP-G28
- Placebo (Type: PLACEBO_COMPARATOR): Study Drug Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).